Mr. William Williams reports

BRIACELL PARTNERS WITH UNEEDLE FOR SCALABLE MICRONEEDLE ADMINISTRATION OF BRIA-IMT™

Briacell Therapeutics Corp. has entered into a memorandum of understanding (MOU), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of Briacell's lead phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer.

• Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration.
• Technology is currently used in Briacell's pivotal phase 3 study and is designed to support faster, more convenient administration while enhancing the patient and provider experience.
• Bria-IMT is currently being evaluated in Briacell's continuing pivotal phase 3 study in advanced metastatic breast cancer.

The MoU reflects the continued commitment of Briacell and Uneedle to collaborate on the potential regulatory and commercial development of Briacell's cell-based immunotherapy Bria-IMT. The non-binding MoU is intended to establish a plan that details scaling of Uneedle's microneedle devices for use in commercial quantities. All activities and projections described herein are contingent upon successful regulatory approval of Briacell's lead phase 3 clinical candidate, Bria-IMT, in the relevant jurisdictions.

Bria-IMT is currently being evaluated in Briacell's ongoing pivotal phase 3 study in advanced metastatic breast cancer (ClinicalTrials identifier: NCT06072612). Uneedle's microneedle technology is being used in this pivotal study to intradermally administer Bria-IMT.

"Efficient and reliable drug administration is integral to treating cancer patients," said William V. Williams, MD, president and chief executive officer of Briacell. "Uneedle's microneedle technology is already being used in our pivotal phase 3 study, and we believe this approach may support faster, more convenient administration and a more patient-friendly treatment experience."

"Precision and consistency in intradermal drug delivery are important attributes for therapies administered into the skin," said Jeroen Wissink, chief executive officer of Uneedle. "We are excited to work with Briacell to support the use of our proprietary microneedle technology for Bria-IMT and to help advance delivery readiness ahead of potential commercialization."

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

About Uneedle

Founded in 2008, and based in Enschede, the Netherlands, Uneedle is a drug-delivery device company specializing in design and good-manufacturing-practice-compliant manufacturing of proprietary silicon microneedle platforms for precise intradermal and suprachoroidal drug delivery.

We seek Safe Harbor.